Evidence map›Paper›PMID 42138697›Full record

ArticleAntimicrobial agents and chemotherapy2026

Ceftazidime-avibactam for multidrug-resistant gram-negative infections: outcomes and timing of initiation across 22 U.S. medical centers.

Ashlan J Kunz Coyne, Chloe Judd, Kristen Lucas, Mohammed Al Musawa, Sean Van Helden, Dana Holger, Ali Althubyani, Christine Yost, Sydney VanDorf, Ryan Mynatt and 33 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

43 authors.

Ashlan J Kunz CoyneDepartment of Pharmacy Practice, Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.ORCID 0000-0002-4891-8625
Chloe JuddDepartment of Pharmacy Practice, Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Kristen LucasDepartment of Pharmacy Practice, Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Mohammed Al MusawaDepartment of Pharmacy Practice, Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Sean Van HeldenDepartment of Pharmacy Practice, Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.ORCID 0009-0000-2277-7089
Dana HolgerBarry and Judy Silverman College of Pharmacy, Nova Southeastern University, Fort Lauderdale, Florida, USA.ORCID 0000-0001-7171-7015
Ali AlthubyaniBarry and Judy Silverman College of Pharmacy, Nova Southeastern University, Fort Lauderdale, Florida, USA.
Christine YostCorewell Health William Beaumont University Hospital, Royal Oak, Michigan, USA.
Sydney VanDorfCorewell Health William Beaumont University Hospital, Royal Oak, Michigan, USA.
Ryan MynattUniversity of Kentucky HealthCare, Lexington, Kentucky, USA.
Wesley D KufelState University of New York at Binghamton School of Pharmacy and Pharmaceutical Sciences, Binghamton, New York, USA.ORCID 0000-0001-7703-096X
Jillian HayesDuke University Hospital, Durham, North Carolina, USA.
Connor R DeriDuke University Hospital, Durham, North Carolina, USA.
Rebekah H WrennDuke University Hospital, Durham, North Carolina, USA.
Cara N SlatonOrlando Health, Orlando, Florida, USA.
Taylor MorrisetteDepartment of Clinical Pharmacy and Outcomes Sciences, Medical University of South Carolina College of Pharmacy, Charleston, South Carolina, USA.
Melisa DavisDepartment of Clinical Pharmacy and Outcomes Sciences, Medical University of South Carolina College of Pharmacy, Charleston, South Carolina, USA.
M Gabriela CabanillaDepartment of Pharmacy, University of New Mexico Hospital, Albuquerque, New Mexico, USA.
Elizabeth ShaldDepartment of Pharmacy, University of New Mexico Hospital, Albuquerque, New Mexico, USA.
Bryan P WhiteOU Health University of Oklahoma Medical Center, Oklahoma City, Oklahoma, USA.
Joseph SassineOU Health University of Oklahoma Medical Center, Oklahoma City, Oklahoma, USA.ORCID 0000-0001-8730-8929
James TruongNewYork-Presbyterian Queens Hospital, Queens, New York, USA.
Joshua RosenbergNewYork-Presbyterian Queens Hospital, Queens, New York, USA.
Justin AndradeTouro College of Pharmacy, The Brooklyn Hospital Center, New York, New York, USA.
John CerenzioTouro College of Pharmacy, The Brooklyn Hospital Center, New York, New York, USA.
Natalia MedvedevaStanford University School of Medicine, Stanford, California, USA.
David HaStanford University School of Medicine, Stanford, California, USA.
Taryn A EubankUniversity of Houston College of Pharmacy, Houston, Texas, USA.
Kevin W GareyUniversity of Houston College of Pharmacy, Houston, Texas, USA.
Mark BiagiUW Health SwedishAmerican Hospital, Rockford, Illinois, USA.
Michaela ToddUW Health SwedishAmerican Hospital, Rockford, Illinois, USA.
S Lena Kang-BirkenSanta Barbara Cottage Hospital, Santa Barbara, California, USA.
Caleb RuxYale New Haven Hospital, New Haven, Connecticut, USA.
Kyle C MolinaScripps Health, San Diego, California, USA.
Christopher A JankowskiUF Health Jacksonville, Jacksonville, Florida, USA.ORCID 0000-0002-4948-4320
Kimberly C ClaeysDepartment of Pharmacy Science and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.ORCID 0000-0001-6895-604X
Veena VenugopalanCollege of Pharmacy, University of Florida, Gainesville, Florida, USA.
Michael P VeveHenry Ford Hospital, Detroit, Michigan, USA.
Carolina OrzolDepartment of Pharmacy Practice, Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Mirna EshayaDepartment of Pharmacy Practice, Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Kaylee E CaniffDepartment of Pharmacy Practice, Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Callan BleickDepartment of Pharmacy Practice, Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
Michael J RybakDepartment of Pharmacy Practice, Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.ORCID 0000-0003-2220-0081

Funding

AbbVie NA
6 · The paper itself

Abstract

Ceftazidime-avibactam (CAZ-AVI) is a crucial treatment for multidrug-resistant (MDR) gram-negative infections; however, the impact of treatment timing and outcomes in real-world practice remains unclear. This study evaluated CAZ-AVI use across diverse U.S. centers, with emphasis on early initiation. We conducted a retrospective cohort study at 22 U.S. medical centers (2019-2025), including adults with MDR gram-negative infections who received CAZ-AVI ≥ 72 h. The primary outcome was composite clinical success, defined as 30-day survival, absence of microbiological recurrence, and resolution of fever and/or leukocytosis within 72 h of initiation. Early vs late initiation was assessed at 48 h. Classification and regression tree (CART) analysis was used to identify optimal thresholds. Among 613 patients (median age 60 years, 62.5% male, 57.1% admitted to the ICU within 24 h of index culture), the most common infection source was pneumonia (55.5%), and the most frequent pathogens were

Indexed as

Anti-Bacterial AgentsAzabicyclo CompoundsCeftazidimeGram-Negative Bacterial InfectionsAgedDrug CombinationsDrug Resistance, Multiple, BacterialFemaleHumansMaleMiddle AgedPseudomonas aeruginosaRetrospective StudiesTreatment OutcomeUnited StatesAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsCeftazidimeDrug Combinationsantimicrobial resistancecarbapenem-resistant Enterobacteralesceftazidime/avibactamearly initiationgram-negative infectionsmultidrug-resistantPseudomonas aeruginosarapid diagnosticsreal-world evidence

Identifiers

PMID42138697
PMCPMC13231909

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.